TCT-22 The STENTYS Self-Expanding Drug-Eluting Stent in Coronary Bifurcation Lesions at 6 Months Follow-up: Results from the OPEN II Trial  by Naber, Christoph et al.
Table. Clinical Outcomes at 12 Months Stratiﬁed According to rSS and bSS
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ID-TVF, n (%) 16 (2.87) 28 (4.31) 63 (9.75) 0.1811 0.0001 <0.0001 <0.0001
Cardiac Death,
n (%)
0 (0.00) 3 (0.46) 6 (0.93) 0.2536 0.3411 0.0334 0.0661
TVMI, n (%) 8 (1.43) 19 (2.93) 34 (5.26) 0.0802 0.0339 0.0003 0.0008
ID-TVR, n (%) 8 (1.43) 7 (1.08) 30 (4.64) 0.5787 0.0001 0.0015 <0.0001
Residual Syntax
score
Low (rSS¼0) Mid
(0<rSS<¼5)
High (rSS>5) p-Value
n¼1190 n¼403 n¼258 * Low vs. Mid * Mid vs. High * Low vs. High All Groups
ID-TVF, n (%) 52 (4.37) 28 (6.95) 26 (10.08) 0.0405 0.1518 0.0002 0.0008
Cardiac Death,
n (%)
2 (0.17) 3 (0.74) 4 (1.55) 0.1064 0.4406 0.0110 0.0091
TVMI, n (%) 27 (2.27) 17 (4.22) 17 (6.59) 0.0390 0.1783 0.0002 0.0010
ID-TVR, n (%) 25 (2.10) 9 (2.23) 10 (3.88) 0.8737 0.2176 0.0924 0.2317
* p value <0.0167 was considered statistically signiﬁcant.
Table. Clinical Outcomes at 1- and 2-Year
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Clinical Follow-Up,
% (n)
99.6 (226) 100 (231) 0.50 99.6 (226) 100 (231) 0.50
Dual Antiplatelet
Therapy,
% (n/N)
92.4 (208/225) 93.0
(213/229)
0.82 24.9
(56/225)
27.8
(63/227)
0.49
Death, % (n) 0.4 (1) 0.9 (2) 1.00 0.4 (1) 0.9 (2) 1.00
Cardiac Death 0.4 (1) 0 (0) 1.00 0.4 (1) 0 (0) 1.00
Non Cardiac Death 0 (0) 0.9 (2) 0.50 0 (0) 0.9 (2) 0.50
Myocardial
Infarction, % (n)
1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50
Q Wave MI 0 (0) 0 (0) - 0 (0) 0 (0) -
Non Q Wave MI 1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50
Target Vessel MI 1.3 (3) 1.7 (4) 1.00 1.3 (3) 1.7 (4) 1.00
Ischemia-Driven
TLR, % (n)
0.4 (1) 0.4 (1) 1.00 0.9 (2) 0.9 (2) 1.00
Any
Revascularization,
% (n)
1.8 (4) 4.8 (11) 0.07 2.2 (5) 6.1 (14) 0.04
*Device-Oriented
Composite
Endpoint (TLF), %
(n)
2.2 (5) 2.2 (5) 1.00 2.7 (6) 2.6 (6) 0.97
**Patient-Oriented
Composite
Endpoint, % (n)
3.5 (8) 7.4 (17) 0.07 4.0 (9) 8.7 (20) 0.04
Deﬁnite or
Probable Stent
Thrombosis, % (n)
0 (0) 0 (0) - 0 (0) 0 (0) -
*Device-Oriented Composite Endpoint (TLF) deﬁned as the composite of cardiac death, target
vessel MI, or ischemia-driven TLR.
**Patient-Oriented Composite Endpoint deﬁned as the composite of all cause death, all MI, or
any revascularization.
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biodegradable polymer SES FIREHAWK was comparable to the durable polymer
EES XIENCE V with respect to the TLF and its components at two years for treating
patients with single de novo native coronary lesions. The incidences of clinical
endpoints were low in both groups. (ClinicalTrials.gov Identiﬁer: NCT01196819).
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Background: Previous studies demonstrated the safety and efﬁcacy of the 2nd
generation drug-eluting stent in treating patients with simple to complex coronary
lesions. The Syntax score has been proposed as a valuable tool to characterize the
coronary anatomy prospectively with respect to its complexity. However, the prog-
nostic value of baseline Syntax score (bSS) and residual Syntax score (rSS) in patients
with complex lesions treated by XIENCE V everolimus-eluting stent (Abbott
Vascular, Santa Clara, CA, USA) on adverse outcomes have not been validated.
Methods: SEEDS was a prospective, multicenter registry study designed to enroll up
to 1900 patients with small vessel (reference vessel diameter <¼ 2.75mm), long
lesion (length >¼ 25mm), or multivessel disease (>¼ 2 target vessels) suitable for
treatment with XIENCE V at 48 centers in China mainland, Macao and Taiwan. The
primary outcome was ischemia-driven target vessel failure (ID-TVF), deﬁned as the
composite of cardiac death, target vessel myocardial infarction (TVMI), or ischemia-
driven target vessel revascularization (ID-TVR) at 12 months. The bSS stratiﬁed
into low (<¼6), mid (>6 and <¼12) and high (>12) and rSS into low (<¼0), mid
(>0 and <¼5) and high (>5) tertiles were applied in all patients.
Results: The mean of bSS was 10.87  7.26, and after PCI the rSS was 2.18  3.97.
At 12 months the primary outcome ID-TVF and its components cardiac death, TVMI,
and ID-TVR were 5.95%, 0.47%, 3.32%, and 2.47%, respectively. The table shows
the clinical outcomes stratiﬁed according to rSS and bSS.B8 JACC Vol 62/18/Suppl B j October 27–NovembConclusions: Signiﬁcantly higher rates of 12-month ID-TVF were observed in the
highest baseline and residual Syntax score groups, indicating that baseline and
residual Syntax score might be the useful tools to predict clinical outcomes in complex
patients treating with 2nd generation everolimus-eluting stent (ClinicalTrials.gov
identiﬁer: NCT 01157455).Bifurcation and Left Main Stenting
Moscone West, 3rd Floor, Room 3020
Tuesday, October 29, 2013, 1:00 PM–3:00 PM
Abstract nos: 22-29
TCT-22
The STENTYS Self-Expanding Drug-Eluting Stent in Coronary Bifurcation
Lesions at 6 Months Follow-up: Results from the OPEN II Trial
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Background: In bifurcation lesions (15-20% of PCIs), results of PCI with balloon
expandable stents are often impaired by carina incomplete support, strut deformation,
malapposition, or excessive metallic burden when treated with 2 stents. Dedicated
stents were developed but they often require precise and difﬁcult positioning or
require to stent ﬁrst the side branch. There is thus a need for an easy to use stent in
most bifurcations and which follows guideline practice of main branch (MB) provi-
sional stenting, supporting carina with minimal disruption of the side branch (SB)
anatomy. The self-expanding STENTYS DES (Stentys, Paris, France) has dis-
connectable struts for side branch access and showed very high procedural success and
low MACE rate in the OPEN I trial.
Methods: The OPEN II prospective, multi-centric single-arm study assess the safety
and efﬁcacy at 6 and 12-months of the STENTYS Paclitaxel eluting stent in routine
coronary bifurcation stenosis. Key exclusion criteria were Medina class 0,0,1, chronic
total occlusion, unprotected left main, and STEMI as clinical presentation. SB stenting
was left to operator's discretion. The primary endpoint of the study is MACE at 6
months follow-up. Secondary endpoints include MACE rate at 12 months, targeter 1, 2013 j TCT Abstracts/ORAL/Bifurcation and Left Main Stenting
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QCA (MLD, DS%, .). An OCT substudy investigates stent apposition at the initial
procedure timepoint.
Results: 220 patients were enrolled in 21 European centers. Age was 6611 years,
78% male. Diabetes was present in 30% of patients, hypertension in 76%. Medina
class 1,1,1 was found in 35% of the patients. STENTYS DES was implanted
successfully in 98% of the patients. Stenting of SB was performed in 12% of the
procedures. Revascularization was successful (TIMI 3 or 2) in 99.5% for MB, and
96.7% for SB.
Conclusions: The ongoing Open II study is the largest study assessing self-expanding
STENTYS DES in bifurcation lesions in a clinical routine setting. The primary
endpoint, MACE rate at 6 months, will be presented, and compared to landmark trials
(Nordic and BBC studies). TVF, QCA and OCT data will also be presented.
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Background: We sought to investigate the clinical impact of the use of intravascular
ultrasound (IVUS) during revascularization of patients with left main (LM) disease
with drug-eluting stents (DES). Whether the use of IVUS during the procedure adds
a clinical beneﬁt remains unclear. There is only one previous observational study with
relevant limitations supporting the value of this strategy.
Methods:We performed a patient level pooled analysis of 4 registries of patients with
LM disease treated with DES. A propensity score matching method was used to obtain
matched pairs of patients with and without IVUS guidance.
Results: A total of 1,670 patients were included and 505 patients (30.2%) underwent
PCI under IVUS guidance (IVUS group). By means of the matching method, 505
patients without the use of IVUS during PCI were selected (no-IVUS group). Survival
free of cardiac death, myocardial infarction and TLR at 3 years was 88.7% in IVUS
group and 83.6% in no-IVUS group (p¼0.04) for overall population and 90% and
80.7% respectively (p¼0.03) for the subgroups with distal LM lesions. The incidence
of deﬁnite and probable thrombosis was signiﬁcantly lower in IVUS group (0.6% vs.
2.2%; p¼0.04). Finally, IVUS resulted independent predictor for major adverse events
in overall population (HR 0.70, 95% CI 0.52 – 0.99; p¼0.04) and in the subgroup with
distal lesions (HR 0.54, 95% CI 0.34 – 0.90; p¼0.02).
Conclusions: The results of this nation-wide registries pooled analysis conﬁrms the
clinical beneﬁt derived from IVUS-guided strategy in patients with LM disease
undergoing PCI with DES, especially in distal lesions.
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Background: The very long term outcome after left main stenting (LEMANS) in
comparison wit surgical revascularization remains unknown. Therefore we report a 10
year clinical follow-up of patients enrolled in the prospective, randomized LEMANS
trial.
Methods: We randomly assigned 105 patients with unprotected left main coronary
artery stenosis (ULMCA) to percutaneous coronary intervention (PCI; 52 patients) or
coronary artery bypass grafting (CABG; 53 patients). Study design, protocol and mid-
term results were reported previously. In the current study, the mean long term follow
up was collected at 9.8  1 years after baseline procedure. Data on all cause mortalityJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrwere collected from all patients, whereas incidence of MACCE, which included all
cause death, myocardial infarction, stroke, repeated revascularization, from 90%.
Results: At ten years, the mortality was comparable between stenting group when
compared to surgery (23.0% vs. 28.7% p¼0.69). Similarly, the incidence of MACCE
was statistically not different to surgery (51.1 vs. 64.4%, p¼0.28), however numeri-
cally the difference was in favor of stenting. The probability of long term survival up
to 14 years was comparable between PCI and CABG (74.2 vs. 67.5%, p¼0.34
HR:1.45 95%CI: 0.67-3.13), however there was a trend toward higher MACCE-free
survival in the PCI group (34.7 vs 22.1%, p¼0.06, HR :1.71 95%CI: 0.97-2.99,
Figure).Conclusions: Left main stenting offers favorable long term outcomes up to 10 years
and constitutes an alternative therapy for CABG.
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Background: The present study aimed to compare the long term (5-year) safety and
efﬁcacy between the one-stent, two stent, and DK crush strategies, utilizing drug-
eluting stents, for unprotected left main coronary artery (ULMCA) bifurcation lesions.
Methods: Between March 2004 and April 2007, 633 consecutive patients with
ULMCA bifurcation lesions (232 in one-stent group and 401 in two-stent group) were
prospectively enrolled. The primary endpoint was the occurrence of major adverse
cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI), and
target vessel revascularization (TVR), at 5-year follow-up.
Results: Patients in the two-stent group were classiﬁed as DK crush (n¼155) and the
other two-stent techniques (culotte, T stenting, Kissing stenting and classical crush,
n¼246). Forty-seven (16.8%) patients in the one-stent group crossed-over to the two-
stent group. The one-stent group was associated with increased incidence of MI
compared to the two-stent approach (10.5% vs. 5.5%, p¼0.025). The crude rate of
MACE at 5-year was 28.0% in one-stent group and 28.4% in two-stent group
(p¼0.927). DK crush was associated with a signiﬁcantly decreased 5-year MACE
compared to other two-stent approaches or the one-stent approach (DK-crush: 14.8%
vs. Other two-stent approaches: 37.0%, one-stent approach: 28.0%, p<0.001). The
main beneﬁt of DK-crush appeared to be primarily secondary to a reduction in TVR
(7.7% vs. 30.5% vs. 18.1%, p<0.001). By Cox regression analyses, the non-DK crush
two-stent technique, a high SYNTAX score (33) or New Risk Stratiﬁcation (NERS)
score (>20), and incomplete revascularization were shown to be independent
predictors of MACE at 5-year follow-up.
Conclusions: With distal left main true bifurcations, the two-stent technique
(excluding DK-crush) is an independent predictor of long term MACE. DK-crush is
associated with more favorable long-term clinical outcomes. Conﬁrmation of these
ﬁndings is required from randomized controlled trials.acts/ORAL/Bifurcation and Left Main Stenting B9
